Genetically informed screening: MGB Biobank
What this study tests
A planned observational recall study asking whether genetic risk can help identify adults with early T1D. It compares the top 2.5% of a T1D polygenic score with the remainder of an existing biobank cohort.
Editorial review: . What was checked and what remains uncertain.
Registry checked: 2026-09-16. Registry’s own update: 2026-09-08.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews.
Evidence at a glance
- Who can enter the study?
- Adults aged 18–79 already enrolled in the Mass General Brigham Biobank who agreed to recontact. This is not an open national screening service. Exclusions include immune checkpoint inhibitor exposure and diabetes secondary to pancreatic disease. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted; not yet recruiting. The registry plans 150 participants. Autoantibody positivity and the added predictive value of clinical features are research outcomes, not proof that the proposed strategy improves health.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read this trial’s review notes for the checks completed and what remains unresolved. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Comparisons between high genetic risk vs. the rest of the cohort — 12 months
The full picture
What the study asks
A planned observational recall study asking whether genetic risk can help identify adults with early T1D. It compares the top 2.5% of a T1D polygenic score with the remainder of an existing biobank cohort.
Who it involves
Adults aged 18–79 already enrolled in the Mass General Brigham Biobank who agreed to recontact. This is not an open national screening service. Exclusions include immune checkpoint inhibitor exposure and diabetes secondary to pancreatic disease. This is a summary; the full registry lists additional criteria.1
Design and timing
The registry lists 150 participants (estimated enrollment). Primary completion: 2029-10-01 (estimated). Study completion: 2030-10-01 (estimated). Estimated dates can change and do not mean results are available.1
Evidence and limits
No results posted; not yet recruiting. The registry plans 150 participants. Autoantibody positivity and the added predictive value of clinical features are research outcomes, not proof that the proposed strategy improves health.
References
-
ClinicalTrials.gov. NCT07802496. Record checked 16 September 2026; last update posted 2026-09-08. https://clinicaltrials.gov/study/NCT07802496 ↩ ↩2
Sources
- [1]Genetically Informed Screening for Early-Stage Type 1 Diabetes (NCT07802496) · registry — Protocol and current registry status checked 16 September 2026.